Pharmaceutical Business review

GSK Appoints New SVP For Medicines Discovery, Development

Prior to joining GSK in 2006, Patrick was a clinical academic and led the division of medicine at UCL. He has over 20 years of experience of clinical medicine and has an international reputation as a vascular biologist and clinician scientist. He was elected to the Academy of Medical Sciences in 1999, and subsequently became its Registrar before leaving to join GSK.

Andrew Witty, CEO of GSK, said: “Patrick has a deep level of scientific and medical acumen, which coupled with his proven management skills, mean he is well placed to bring further R&D perspective to GSK’s leadership team.

“This appointment aligns with the company’s drive to increase R&D productivity and deliver more products of value. I look forward to working with Patrick in his new role and welcome him to the executive team.”